Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over compounded GLP-1 medications.
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's ...
At the time, Teladoc Health was hailed as the ultimate telemedicine darling; its stock price skyrocketed to nearly $300 per ...
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
Hims & Hers Health (NYSE: HIMS) has built its brand up in recent years by focusing on offering its customers products related to sensitive issues such as hair loss and erectile dysfunction.
Telehealth company Hims & Hers Health (NYSE: HIMS) has been great for investors this year by almost any standard; share prices have nearly doubled from a year ago. Yet shareholders aren't ...
Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...
As is often the case with investing (and in life), a new player has entered the telemedicine arena: Hims & Hers Health (NYSE: HIMS). Could Hims & Hers Health be a lucrative investment ...
Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...
Tesla extends losses following the release of third-quarter deliveries, and Levi Strauss tumbles after cutting its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback